Rilotumumab, CAS 872514-65-3

Product Description: Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87./[2]Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24.

CAS Number: 872514-65-3

Molecular Weight: N/A

Compound Purity: 99.10

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: c-Met/HGFR

• Artikelnummer: MEXHY-P99217-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99217-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK